SCHEMBL1521844

SCHEMBL1521844

CCN1C(=O)N(c2cc(NC(=O)NC3CCCCC3)c(F)cc2C)Cc2cnc(NC)cc21

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.42
FGFR4 P22455 3/20 0.42
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
POLB P06746 1/20 0.38
RAF1 P04049 4/20 0.37
BRAF P15056 4/20 0.37
KRAS P01116 3/20 0.37
KDR P35968 3/20 0.37
MAP2K2 P36507 3/20 0.37
MAP2K1 Q02750 3/20 0.37
PARP1 P09874 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 2/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
EPHX2 P34913 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ARAF P10398 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521987 0.88 FGFR1 (0.43) FGFR1FGFR4RAB9ANPC1POLB
SCHEMBL1521617 0.86 RAF1 (0.37) RAB9ANPC1POLBRAF1BRAF
SCHEMBL1521797 0.85 TNK2 (0.37) FGFR1FGFR4RAB9ANPC1POLB
SCHEMBL1521657 0.81 TRPV1 (0.42) FGFR1FGFR4RAB9ANPC1RAF1
SCHEMBL1521672 0.81 BRAF (0.40) FGFR1FGFR4RAF1BRAFKRAS
SCHEMBL1521431 0.80 BRAF (0.52) FGFR1FGFR4RAF1BRAFKRAS
SCHEMBL1521565 0.80 KDR (0.46) FGFR1RAF1BRAFKDRKMT2A
SCHEMBL1521761 0.80 TAS1R3 (0.35) FGFR4RAF1BRAFKRASKDR
SCHEMBL1521476 0.79 FGFR4 (0.41) FGFR1FGFR4FGFR2FGFR3
SCHEMBL1521947 0.77 RAB9A (0.41) RAB9ANPC1POLBPARP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 FGFR1 577/4885FGFR4 1073/4885RAB9A 1244/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR1 577/4885FGFR4 1073/4885RAB9A 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.